CLINICAL ROLE -
How Can Specialty Pharmacy Achieve the Goals of ACOs
National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the relationship between specialty pharmacies and accountable care organizations.
Read More
Will Biosimilars Reduce Specialty Drug Spending?
National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.
Payer Denial of Routine Care Costs Highlight Week in Health Care News
Catch up with the latest developments across the health care landscape and sign up for key upcoming conferences.
Promising New Drug Adherence Program Highlights Week in Specialty Pharmacy
Most read articles of the week on Specialty Pharmacy Times.
The Challenge of High Cost Drugs in Specialty Pharmacy
Michael Zeglinski, vice president of Specialty Pharmacy Operations at BriovaRx, discusses how expensive hepatitis C drugs have impacted the specialty landscape.
Optimal Use of Data Analytics for Specialty Pharmacy
David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, discusses how specialty pharmacies can enhance their operations with data analytics.
NFL Legend Talks Prostate Cancer Fight; Doctor Pay Rates Highlight Week in Health Care News
Catch up with the latest developments across the health care landscape and sign up for key upcoming conferences and continuing education activities.
Drug Approvals Highlight AJPB Week in Review
Catch up with the top news of the week from The American Journal of Pharmacy Benefits.
FDA Approves New Hepatitis C Therapy
Zepatier is a once-daily, fixed-dose combination containing with the NS5A inhibitor elbasvir and the NS3/4A protease inhibitor grazoprevir.
Hep C, Melanoma Drug Approvals Highlight Week in Specialty Pharmacy
Top stories of the week on Specialty Pharmacy Times.
Prescription Drug Trends, Diabetes Risk in Cancer Survivors Highlight Week in Health Care News
Myeloma, PsA Drug Approvals Highlight Week in Specialty Pharmacy News
FDA Approves Relapsed Multiple Myeloma Combination Therapy
Carfilzomib approved in combination with dexamethasone, or with lenalidomide plus dexamethasone, for patients with relapsed/refractory multiple myeloma.
Emerging Trends in Specialty Pharmacy
David Lassen, chief clinical officer at Prime Therapeutics, discusses important developments in specialty pharmacy.
Medicare Prescription Drug Benefit Not a Cost Saver
Study finds that Medicare Part D cost saving projections are based on flawed methodology.
The Benefits of Pharmacy Accreditation
Heather Bonome, PharmD, director of Pharmacy Segment at URAC, discusses what comprises an effective pharmacy accreditation program.
Government-Backed Cancer Fighting Initiative Tops Week in Health Care News
Hepatitis C Cure, Multiple Myeloma Trial in Top Specialty Pharmacy News
Multiple Myeloma Monotherapy Shows Strong Overall Response Rate
Study shows promising results for previously treated or refractory patients with multiple myeloma.
The Changing Landscape for Specialty Pharmacy Patients
Marc O'Connor, chief operating officer of Curant Health, discusses potential changes patients of specialty pharmacies may experience in the near future.
Pfizer Raises Prices on More Than 100 Drugs
Cost of some drugs jump by as much as 20%.
The Aftermath of Hepatitis C Drugs on Specialty Spending
David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.
New Dietary Guidelines, Cancer Treatment Advances Highlight the Week in Health Care News
Medicare Does Little to Alleviate High Cost of Oral Chemotherapy Drugs
Out-of-pocket costs to remain a significant hurdle for patients even after closing of coverage gap.